[96a5a0]: / output / allTrials / identified / NCT01886573_identified.json

Download this file

721 lines (721 with data), 33.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
{
"info": {
"nct_id": "NCT01886573",
"official_title": "Genome-Wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-Treatment With 5-Azacytidine and Entinostat",
"inclusion_criteria": "* Undergoing a diagnostic biopsy, including computed tomography (CT)-guided or bronchoscopic for suspected diagnosis of NSCLC\n* Able to understand and sign an informed consent discussing the risks and benefits of obtaining a concurrent research biopsy; patients who have a fresh frozen biopsy available secondary to institutional tissue collection protocols may substitute such a biopsy for the study-required pre-treatment biopsy\n* Histologically confirmed diagnosis of operable NSCLC that has not been previously treated\n* Clinical stage IA-IIIA\n* Appropriate candidate for surgical management, in the opinion of the treating thoracic surgeon\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2 at the time of initiation of neoadjuvant epigenetic therapy\n* Absolute neutrophil count > 1,000/mcL\n* Platelets > 100,000/mcL\n* Total bilirubin < 1.5 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional ULN\n* Creatinine < 1.5 x institutional ULN\n* Able to understand and sign an informed consent\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Inclusion of women and minorities:\n\n * Both men and women and members of all races and ethnic groups are eligible for this trial; the coordinating center will be responsible for ensuring each participating site is accruing a representative sample consistent with the estimate of population representation in the site's geographical location for race and ethnic groups as determined by the Census Bureau to assure overall target goals are met\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients who have received prior chemotherapy or radiation for their diagnosis of lung cancer\n* Patients may not be receiving any other investigational agent\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat or 5-azacytidine\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol\n* Any co-morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications\n* Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible\n* Known or suspected hypersensitivity to azacitidine or mannitol\n* Patients with advanced malignant hepatic tumors\n* Use of anti-neoplastic or anti-tumor agents that are not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy, is not permitted while participating in this study; Note: study participants with stage II or III NSCLC, or stage I NSCLC with tumor size greater than 4 cm, should be offered standard adjuvant platinum-based chemotherapy in accordance with local practice (post-operatively)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Undergoing a diagnostic biopsy, including computed tomography (CT)-guided or bronchoscopic for suspected diagnosis of NSCLC",
"criterions": [
{
"exact_snippets": "Undergoing a diagnostic biopsy",
"criterion": "diagnostic biopsy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "computed tomography (CT)-guided or bronchoscopic",
"criterion": "biopsy method",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"computed tomography (CT)-guided",
"bronchoscopic"
]
}
]
},
{
"exact_snippets": "suspected diagnosis of NSCLC",
"criterion": "suspected diagnosis of NSCLC",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Able to understand and sign an informed consent discussing the risks and benefits of obtaining a concurrent research biopsy; patients who have a fresh frozen biopsy available secondary to institutional tissue collection protocols may substitute such a biopsy for the study-required pre-treatment biopsy",
"criterions": [
{
"exact_snippets": "Able to understand and sign an informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "patients who have a fresh frozen biopsy available",
"criterion": "fresh frozen biopsy",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
}
]
},
{
"line": "* Histologically confirmed diagnosis of operable NSCLC that has not been previously treated",
"criterions": [
{
"exact_snippets": "Histologically confirmed diagnosis",
"criterion": "diagnosis confirmation",
"requirements": [
{
"requirement_type": "method",
"expected_value": "histologically"
}
]
},
{
"exact_snippets": "operable NSCLC",
"criterion": "NSCLC operability",
"requirements": [
{
"requirement_type": "operability",
"expected_value": true
}
]
},
{
"exact_snippets": "NSCLC that has not been previously treated",
"criterion": "NSCLC treatment history",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": "not previously treated"
}
]
}
]
},
{
"line": "* Clinical stage IA-IIIA",
"criterions": [
{
"exact_snippets": "Clinical stage IA-IIIA",
"criterion": "clinical stage",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "A"
},
{
"operator": "<=",
"value": 3,
"unit": "A"
}
]
}
}
]
}
]
},
{
"line": "* Appropriate candidate for surgical management, in the opinion of the treating thoracic surgeon",
"criterions": [
{
"exact_snippets": "Appropriate candidate for surgical management, in the opinion of the treating thoracic surgeon",
"criterion": "surgical management candidacy",
"requirements": [
{
"requirement_type": "opinion",
"expected_value": "treating thoracic surgeon"
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2 at the time of initiation of neoadjuvant epigenetic therapy",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Absolute neutrophil count > 1,000/mcL",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count > 1,000/mcL",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 1000,
"unit": "mcL"
}
}
]
}
]
},
{
"line": "* Platelets > 100,000/mcL",
"criterions": [
{
"exact_snippets": "Platelets > 100,000/mcL",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 100000,
"unit": "mcL"
}
}
]
}
]
},
{
"line": "* Total bilirubin < 1.5 x institutional upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": "Total bilirubin < 1.5 x institutional upper limit of normal (ULN)",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "x institutional upper limit of normal (ULN)"
}
}
]
}
]
},
{
"line": "* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional ULN",
"criterions": [
{
"exact_snippets": "Aspartate aminotransferase (AST) ... < 2.5 x institutional ULN",
"criterion": "aspartate aminotransferase (AST)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.5,
"unit": "x institutional ULN"
}
}
]
},
{
"exact_snippets": "alanine aminotransferase (ALT) ... < 2.5 x institutional ULN",
"criterion": "alanine aminotransferase (ALT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.5,
"unit": "x institutional ULN"
}
}
]
}
]
},
{
"line": "* Creatinine < 1.5 x institutional ULN",
"criterions": [
{
"exact_snippets": "Creatinine < 1.5 x institutional ULN",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "x institutional ULN"
}
}
]
}
]
},
{
"line": "* Able to understand and sign an informed consent",
"criterions": [
{
"exact_snippets": "Able to understand",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "ability",
"expected_value": "understand"
}
]
},
{
"exact_snippets": "sign an informed consent",
"criterion": "ability to sign informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",
"criterions": [
{
"exact_snippets": "Women of child-bearing potential ... must agree to use adequate contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "men must agree to use adequate contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "should a woman become pregnant ... she should inform her treating physician immediately",
"criterion": "pregnancy notification",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Inclusion of women and minorities:",
"criterions": [
{
"exact_snippets": "Inclusion of women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "inclusion",
"expected_value": "female"
}
]
},
{
"exact_snippets": "Inclusion of ... minorities",
"criterion": "ethnicity",
"requirements": [
{
"requirement_type": "inclusion",
"expected_value": "minorities"
}
]
}
]
},
{
"line": "* Both men and women and members of all races and ethnic groups are eligible for this trial; the coordinating center will be responsible for ensuring each participating site is accruing a representative sample consistent with the estimate of population representation in the site's geographical location for race and ethnic groups as determined by the Census Bureau to assure overall target goals are met",
"criterions": [
{
"exact_snippets": "Both men and women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "inclusion",
"expected_value": [
"men",
"women"
]
}
]
},
{
"exact_snippets": "members of all races and ethnic groups",
"criterion": "race and ethnicity",
"requirements": [
{
"requirement_type": "inclusion",
"expected_value": "all races and ethnic groups"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients who have received prior chemotherapy or radiation for their diagnosis of lung cancer",
"criterions": [
{
"exact_snippets": "Patients who have received prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients who have received prior ... radiation",
"criterion": "prior radiation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "diagnosis of lung cancer",
"criterion": "lung cancer diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients may not be receiving any other investigational agent",
"criterions": [
{
"exact_snippets": "Patients may not be receiving any other investigational agent",
"criterion": "investigational agent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat or 5-azacytidine",
"criterions": [
{
"exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat or 5-azacytidine",
"criterion": "allergic reactions",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "attribution",
"expected_value": [
"compounds of similar chemical or biologic composition to entinostat",
"compounds of similar chemical or biologic composition to 5-azacytidine"
]
}
]
}
]
},
{
"line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
"criterions": [
{
"exact_snippets": "Uncontrolled intercurrent illness ... ongoing or active infection",
"criterion": "ongoing or active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... symptomatic congestive heart failure",
"criterion": "symptomatic congestive heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... unstable angina pectoris",
"criterion": "unstable angina pectoris",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... cardiac arrhythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... psychiatric illness/social situations that would limit compliance with study requirements",
"criterion": "psychiatric illness/social situations",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": false
}
]
}
]
},
{
"line": "* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol",
"criterions": [
{
"exact_snippets": "Pregnant women are excluded",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding should be discontinued",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "status",
"expected_value": "discontinued"
}
]
}
]
},
{
"line": "* Any co-morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications",
"criterions": [
{
"exact_snippets": "Any co-morbid condition ... renders the patient at high risk from treatment complications",
"criterion": "co-morbid condition",
"requirements": [
{
"requirement_type": "risk assessment",
"expected_value": "high risk from treatment complications"
}
]
}
]
},
{
"line": "* Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible",
"criterions": [
{
"exact_snippets": "Human immunodeficiency virus (HIV) positive",
"criterion": "HIV status",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "on combination antiretroviral therapy",
"criterion": "combination antiretroviral therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Known or suspected hypersensitivity to azacitidine or mannitol",
"criterions": [
{
"exact_snippets": "Known or suspected hypersensitivity to azacitidine",
"criterion": "hypersensitivity to azacitidine",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Known or suspected hypersensitivity to ... mannitol",
"criterion": "hypersensitivity to mannitol",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with advanced malignant hepatic tumors",
"criterions": [
{
"exact_snippets": "advanced malignant hepatic tumors",
"criterion": "hepatic tumors",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
},
{
"requirement_type": "malignancy",
"expected_value": true
}
]
}
]
},
{
"line": "* Use of anti-neoplastic or anti-tumor agents that are not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy, is not permitted while participating in this study; Note: study participants with stage II or III NSCLC, or stage I NSCLC with tumor size greater than 4 cm, should be offered standard adjuvant platinum-based chemotherapy in accordance with local practice (post-operatively)",
"criterions": [
{
"exact_snippets": "Use of anti-neoplastic or anti-tumor agents that are not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy, is not permitted while participating in this study",
"criterion": "use of anti-neoplastic or anti-tumor agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "study participants with stage II or III NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"II",
"III"
]
}
]
},
{
"exact_snippets": "stage I NSCLC with tumor size greater than 4 cm",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "I"
}
]
},
{
"exact_snippets": "stage I NSCLC with tumor size greater than 4 cm",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">",
"value": 4,
"unit": "cm"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}